Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction
Portfolio Pulse from
Windtree Therapeutics has partnered with New Growth Advisors to explore strategic transactions for its cardiovascular portfolio, following positive Phase 2 results for Istaroxime in cardiogenic shock.
December 04, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Windtree Therapeutics has engaged New Growth Advisors to explore strategic transactions for its cardiovascular portfolio, potentially including out-licensing or asset sales, following positive Phase 2 results for Istaroxime.
The partnership with New Growth Advisors indicates Windtree's intent to capitalize on the positive Phase 2 results of Istaroxime. This could lead to strategic transactions such as out-licensing or asset sales, potentially increasing the company's value and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100